CRD-750 is the first clinical-stage PDE9 inhibitor to be evaluated in patients in both types of chronic heart failure The CYCLE-1-REF trial is evaluating patients with heart failure with reduced ...

Assessment of left ventricular systolic function is essential for diagnosing and managing cardiac diseases and provides important prognostic information to the treating clinician. However, traditional ...

A post hoc analysis of the SUMMIT trial, published in JACC, reveals that baseline body mass index (BMI) and fat distribution ...

According to expert presenters at the American Society of Preventive Cardiology’s 2025 Congress on Cardiovascular Disease Prevention, recent studies have shown significant benefit to GLP-1 inhibitors ...

Ultromics has raised $55 million in venture capital funding to expand the reach of its artificial-intelligence-powered ...

Rayan Salih, MD, a third-year internal medicine resident with the Northeast Georgia Health System, who hopes to specialize in cardiology, presented the poster, “Double Trouble: Pregnancy Challenges in ...

Dapagliflozin-spironolactone reduces NT-proBNP levels and blood pressure more than dapagliflozin alone but at the cost of a ...

Glucagon-like peptide-1 (GLP-1) inhibitors have proven effective in preventing cardiovascular events, leading to experts ...

Are men’s and women’s hearts that different? Yes, they are, and knowing those differences could save a woman’s life.

The venture capital arms of Pittsburgh-based UPMC and UChicago Medicine have invested in a healthcare AI startup as part of a $55 million series C funding round. UPMC Enterprises and UCM Ventures ...

A tiny implantable heart device is changing lives for patients with HFpEF heart failure. Scripps La Jolla is among 65 ...

The company said it plans to expand U.S. access to its services while growing its pipeline to include additional cardiac ...